[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100394446":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":29,"responsibleParty":48,"collaborators":19,"id":50,"slug":19,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":19,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: 68Ga-DOTA-FAPI-04","EXPERIMENTAL","Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET\u002FCT imaging within the specified time.",[13],"Diagnostic Test: 18F-FDG and 68Ga-DOTA-FAPI -04 PET\u002FCT",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","18F-FDG and 68Ga-DOTA-FAPI -04 PET\u002FCT",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Hua Wu, PhD","CONTACT","86 0592-2137166","wuhua1025@163.com",{"name":27,"role":23,"phone":24,"phoneExt":19,"email":28},"Haojun Chen, PhD","leochen0821@foxmail.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"First affiliated hospital of xiamen university","RECRUITING","Xiamen","Fujian","0086-361000","China","CN",{"type":39,"coordinates":40},"Point",[41,42],118.08187,24.47979,{"lat":42,"lon":41},[45],{"name":46,"role":23,"phone":47,"phoneExt":19,"email":25},"Hua Wu, doctor","18659285282",{"type":49,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100394446",false,"NCT04416165","Comparison of FDG and FAPI in Patients With Various Types of Cancer","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report); (iii) patients who had scheduled both 18F-FDG and 68Ga-DOTA-FAPI-04 PET\u002FCT scans; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","ALL","18 Years","90 Years",{"count":59,"type":60},3000,"ESTIMATED","INTERVENTIONAL",[63],"NA","To evaluate the potential usefulness of 68Ga-DOTA-FAPI-04 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET\u002FCT.",[66,67,68],"Tumor, Solid","Positron-Emission Tomography","Metastasis",[67,66,70,68],"Diagnosis","2023-08-06",{"date":73,"type":74},"2023-08-08","ACTUAL",{"date":76,"type":74},"2019-10-20",{"date":78,"type":60},"2027-12-30",{"name":5,"class":6},1]